Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.00

+0.2%

12:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: celeryroot.com who wrote (7983)	9/29/1997 12:55:00 PM
From: Andrew H	of 32384

I think 250M is probably about right for the trials on the average although it probably depends a lot on the particular drug. For example, AMLN and JNJ are spending a small fortune on pramlintide, whereas Targretin for CTCL will probably be quite a bit cheaper. Also if a drug like Targretin has many indications, you get a lot more bang for your buck--once the P1s are done, they needn't be repeated for other indications. My guess is you can do it cheaper than 250M for a lot of drugs. Henry should know the deatails. Three years would be a best case scenario for a drug that has just begun P1 and is for a disease where you can see results quickly. It would NOT include FDA processing time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next